- Home
- ENLT vs ARWR Comparison
ENLT vs ARWR Comparison
Compare ENLT & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENLT | ARWR |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.6B |
| IPO Year | 2023 | 1993 |
Fundamental Metrics
Financial Performance| Metric | ENLT | ARWR |
|---|---|---|
| Price | $39.53 | $70.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $37.50 | ★ $60.70 |
| AVG Volume (30 Days) | 30.2K | ★ 3.3M |
| Earning Date | 11-12-2025 | 11-25-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.72 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | $457,756,000.00 | ★ $829,448,000.00 |
| Revenue This Year | $355.90 | N/A |
| Revenue Next Year | $42.83 | N/A |
| P/E Ratio | $42.02 | ★ N/A |
| Revenue Growth | 27.72 | ★ 23258.15 |
| 52 Week Low | $14.01 | $9.57 |
| 52 Week High | $42.38 | $72.36 |
Technical Indicators
Market Signals| Indicator | ENLT | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 78.58 |
| Support Level | $38.97 | $60.29 |
| Resistance Level | $41.95 | $71.50 |
| Average True Range (ATR) | 0.99 | 5.14 |
| MACD | -0.11 | 1.73 |
| Stochastic Oscillator | 75.09 | 95.82 |
Price Performance
Historical ComparisonAbout ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.